ABOUT INDEXING BOARD ARCHIVES AUTHOR GUIDELINES SUBMIT PAPER AUTHOR'S PAGE NEWS, EVENTS CONTACT
REVISTA DE CHIMIE
Cite as: Rev. Chim.
https://doi.org/10.37358/Rev.Chim.1949

OSIM Nr. R102355
ISSN Online 2668-8212
ISSN Print: 1582-9049
ISSN-L: 1582-9049

REVISTA DE CHIMIE Latest Issue

LATEST ISSUE >>>

   Volume 75, 2024
   Volume 74, 2023
   Volume 73, 2022
   Volume 72, 2021
   Volume 71, 2020
   Volume 70, 2019
   Volume 69, 2018
   Volume 68, 2017
   Volume 67, 2016
   Volume 66, 2015
   Volume 65, 2014
   Volume 64, 2013
   Volume 63, 2012
   Volume 62, 2011
   Volume 61, 2010
   Volume 60, 2009
   Volume 59, 2008
   Volume 58, 2007
 
<<<< back

Revista de Chimie (Rev. Chim.), Year 2017, Volume 68, Issue 7, 1652-1659

https://doi.org/10.37358/RC.17.7.5737

Dana Lucia Stanculeanu, Raluca Ioana Mihaila, Daniela Zob, Oana Catalina Toma, Raluca Ioana Mihaila, Elena Toader, Mihaela Boanca, Vladimir Poroch, Laurentiu Simion

Correlation Between the Tyrozinkinazine Inhibitor Sunitinib - Dose, Schedule of Administration and Adverse Events

Abstract:

Sunitinib, a multi-targeted receptor tyrosine kinase inhibitor, has demonstrated survival benefit in patients with metastatic renal cell carcinoma (mRCC) and is generally well tolerated with most adverse events, manifesting as mild to moderate in severity. The most frequent related adverse events include hand-foot syndrome (HFS), hypertension, proteinuria, cardiac toxicities, myelosuppression, fatigue/asthenia, hypothyroidism, diarrhea and hepatotoxicity. The study aims to determine incidence of adverse events among patients with metastatic renal cell carcinoma (mRCC) treated Sunitinib within five years from 2010 to 2015 and comparing the results with data from literature. The study included a total of 56 patients treated with Sunitinib, with a dose of 50 mg (Schedule 4/2). Due to adverse events and individual safety and tolerability, at the indication of the personal clinician, 11 patients needed dose reduction, with a continuous dose of 37.5 mg, daily and 28 patients continued the dose of 50 mg taken daily, on a different schedule (2/1 schedule). The most important toxicities were anemia, leukopenia, thrombocytopenia, gastrointestinal effects (diarrhea), fatigue and hypertension. After dose reduction or modified schedule the incidence of the most frequent toxicities (HFS, leukopenia, thrombocytopenia and fatigue) decreased, but hypertension was still observed in 30% of patients. The results are similar with data from literature. Early identification of individuals at risk and monitoring patients during Sunitinib treatment is very important and it can facilitate early intervention with prophylactic measures or supportive treatment, thus increasing quality of life and adherence to treatment. Further studies need to establish which targeted population can benefit the most from adjusted regimens and to correlate them with prognostic factors for survival.
Keywords:
Sunitinib; tyrosine kinase inhibitor; adverse events; schedule; dose reduction; tolerability

Issue: 2017, Volume 68, Issue 7
Pages: 1652-1659
Publication date: 2017/8/15
https://doi.org/10.37358/RC.17.7.5737
download pdf   Download Pdf Article
Creative Commons License
This article is published under the Creative Commons Attribution 4.0 International License
Citation Styles
Cite this article as:
STANCULEANU, D.L., MIHAILA, R.I., ZOB, D., TOMA, O.C., MIHAILA, R.I., TOADER, E., BOANCA, M., POROCH, V., SIMION, L., Correlation Between the Tyrozinkinazine Inhibitor Sunitinib - Dose, Schedule of Administration and Adverse Events, Rev. Chim., 68(7), 2017, 1652-1659.

Vancouver
Stanculeanu DL, Mihaila RI, Zob D, Toma OC, Mihaila RI, Toader E, Boanca M, Poroch V, Simion L. Correlation Between the Tyrozinkinazine Inhibitor Sunitinib - Dose, Schedule of Administration and Adverse Events. Rev. Chim.[internet]. 2017 Jul;68(7):1652-1659. Available from: https://doi.org/10.37358/RC.17.7.5737


APA 6th edition
Stanculeanu, D.L., Mihaila, R.I., Zob, D., Toma, O.C., Mihaila, R.I., Toader, E.,... Simion, L. (2017). Correlation Between the Tyrozinkinazine Inhibitor Sunitinib - Dose, Schedule of Administration and Adverse Events. Revista de Chimie, 68(7), 1652-1659. https://doi.org/10.37358/RC.17.7.5737


Harvard
Stanculeanu, D.L., Mihaila, R.I., Zob, D., Toma, O.C., Mihaila, R.I., Toader, E., Boanca, M., Poroch, V., Simion, L. (2017). 'Correlation Between the Tyrozinkinazine Inhibitor Sunitinib - Dose, Schedule of Administration and Adverse Events', Revista de Chimie, 68(7), pp. 1652-1659. https://doi.org/10.37358/RC.17.7.5737


IEEE
D.L. Stanculeanu, R.I. Mihaila, D. Zob, O.C. Toma, R.I. Mihaila, E. Toader, M. Boanca, V. Poroch, L. Simion, "Correlation Between the Tyrozinkinazine Inhibitor Sunitinib - Dose, Schedule of Administration and Adverse Events". Revista de Chimie, vol. 68, no. 7, pp. 1652-1659, 2017. [online]. https://doi.org/10.37358/RC.17.7.5737


Text
Dana Lucia Stanculeanu, Raluca Ioana Mihaila, Daniela Zob, Oana Catalina Toma, Raluca Ioana Mihaila, Elena Toader, Mihaela Boanca, Vladimir Poroch, Laurentiu Simion,
Correlation Between the Tyrozinkinazine Inhibitor Sunitinib - Dose, Schedule of Administration and Adverse Events,
Revista de Chimie,
Volume 68, Issue 7,
2017,
Pages 1652-1659,
ISSN 2668-8212,
https://doi.org/10.37358/RC.17.7.5737.
(https://revistadechimie.ro/Articles.asp?ID=5737)
Keywords: Sunitinib; tyrosine kinase inhibitor; adverse events; schedule; dose reduction; tolerability


RIS
TY - JOUR
T1 - Correlation Between the Tyrozinkinazine Inhibitor Sunitinib - Dose, Schedule of Administration and Adverse Events
A1 - Stanculeanu, Dana Lucia
A2 - Mihaila, Raluca Ioana
A3 - Zob, Daniela
A4 - Toma, Oana Catalina
A5 - Mihaila, Raluca Ioana
A6 - Toader, Elena
A7 - Boanca, Mihaela
A8 - Poroch, Vladimir
A9 - Simion, Laurentiu
JF - Revista de Chimie
JO - Rev. Chim.
PB - Revista de Chimie SRL
SN - 2668-8212
Y1 - 2017
VL - 68
IS - 7
SP - 1652
EP - 1659
UR - https://doi.org/10.37358/RC.17.7.5737
KW - Sunitinib
KW - tyrosine kinase inhibitor
KW - adverse events
KW - schedule
KW - dose reduction
KW - tolerability
ER -


BibTex
@article{RevCh2017P1652,
author = {Stanculeanu Dana Lucia and Mihaila Raluca Ioana and Zob Daniela and Toma Oana Catalina and Mihaila Raluca Ioana and Toader Elena and Boanca Mihaela and Poroch Vladimir and Simion Laurentiu},
title = {Correlation Between the Tyrozinkinazine Inhibitor Sunitinib - Dose, Schedule of Administration and Adverse Events},
journal = {Revista de Chimie},
volume = {68},
number = {7},
pages = {1652-1659},
year = {2017},
issn = {2668-8212},
doi = {https://doi.org/10.37358/RC.17.7.5737},
url = {https://revistadechimie.ro/Articles.asp?ID=5737}
}
 
<<<< back
 
PUBLISHING SECTION
Author Guidelines
 * Paper Drafting
 * Paper Template
 * Ethical Statement
 * Paper Submission
Ghidul Autorului (ro)
Submit Paper
Author's Page
Publishing Ethics
Peer Review Process
Open Access & Archiving Policy
 Search Authors
 LATEST NEWS
REvista de Chimie NUMAR OMAGIAL PETRU PONI.. detalii
REvista de Chimie Revista de Chimie - 70 de ani de aparitie neintrerupta.. detalii
dictionar English-Romanian Dictionary for Mechanical Engineering
(download pdf)
  News, Events
Crossref Member Badge
 DOI  logo
 Gold Open Access | Source=http://www.plos.org/  | Author=art designer at PLoS
Creative Commons License
 Conferences of Contemporary
 Chemistry
 Biblioteca Chimiei
 Materiale Plastice